Across TCGA pan-cancer cohorts, SLC25A53 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC25A53 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC25A53 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A53 expression acts as an unfavorable survival marker.
HNSC and LUAD are the cancer types where SLC25A53 Mutation most reproducibly stratifies survival.